featured
Pembrolizumab vs Placebo as Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial
J. Clin. Oncol 2022 Dec 01;[EPub Ahead of Print], S Qin, Z Chen, W Fang, Z Ren, R Xu, BY Ryoo, Z Meng, Y Bai, X Chen, X Liu, J Xiao, GF Ho, Y Mao, X Wang, J Ying, J Li, W Zhong, Y Zhou, AB Siegel, C HaoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.